Patent intelligence · US
US 6869624
Product and process for stabilizing Aloe vera gel
Product and process for stabilizing Aloe vera gel
Patent details — US 6869624
- Jurisdiction
- US
- Status
- expired
- Grant date
- Mar 22, 2005
- Expiration
- Mar 17, 2025
- Applicant
- Aloe Vera of America, Inc.
- Claims
- 20
- CPC classes
- A61K, A61K36/53, A61K36/886
Quick answer
US 6869624 (Product and process for stabilizing Aloe vera gel) is held by Aloe Vera of America, Inc.. Status: expired. Granted Mar 22, 2005. Expires Mar 17, 2025 (0 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- Aloe Vera of America, Inc.
- Grant date
- Expiration
- Claims
- 20
- CPC classes
- A61K, A61K36/53, A61K36/886
More from Aloe Vera of America, Inc.
Related pharmaceutical patents in our USPTO index.
-
US 12403164
Lentiviral vector formulations
granted -
US 12403183
Factor VIII polypeptide formulations
granted -
US 12391750
Anti-C1S antibodies and methods of use thereof
granted -
US 12371747
Methods of reducing immunogenicity against factor VIII in individuals undergoing factor VIII therapy
granted -
US 12364774
Nucleic acid molecules and uses thereof for non-viral gene therapy
granted -
US 12268688
Compositions and methods of use for modified release minoxidil
granted -
US 12257288
Methods of inducing immune tolerance to clotting factors
granted -
US 12240917
Anti-complement C1s antibodies and uses thereof
granted
Frequently asked questions
What is US patent 6869624?
US 6869624 (Product and process for stabilizing Aloe vera gel) is held by Aloe Vera of America, Inc.. Status: expired. Granted Mar 22, 2005. Expires Mar 17, 2025 (0 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 6869624?
Aloe Vera of America, Inc. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 140 pharmaceutical patents for this assignee.
When does US 6869624 expire?
Our index shows an expiration date of Mar 17, 2025 (0 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.